Please login to the form below

Not currently logged in
Email:
Password:

gene-editing

This page shows the latest gene-editing news and features for those working in and with pharma, biotech and healthcare.

Sangamo’s first gene-editing trial doesn’t convince investors

Sangamo’s first gene-editing trial doesn’t convince investors

Sangamo’ s first gene-editing trial doesn’ t convince investors. Market spooked by inconclusive early results. ... gene-editing technology that is designed to modify liver cells to express the iduronate-2-sulfatase or IDS enzyme that is deficient in

Latest news

  • Sanofi gets EU OK for Ablynx flagship drug Cablivi Sanofi gets EU OK for Ablynx flagship drug Cablivi

    of Bioverativ earlier this year which added two marketed haemophilia drugs as well as a pipeline of blood disorder products including genome editing drugs and gene therapies.

  • Allergan builds on gene editing deal Allergan builds on gene editing deal

    Allergan builds on gene editing deal. Irish firm will co-develop CRISPR candidate for vision-threatening disorder. ... genes. The approach has been making the rounds quite recently in the pharma space, but this ground-breaking gene therapy is struggling

  • Boehringer and partners set sights on cystic fibrosis gene therapy Boehringer and partners set sights on cystic fibrosis gene therapy

    be overcome, most notably the huge drug delivery challenge of making an inhalable gene therapy. ... disclosed. Vertex is investing in its own ‘next generation’treatments, and this includes a collaboration in the gene-editing field with CRISPR first

  • Mallinckrodt doses first patient in muscular dystrophy trial Mallinckrodt doses first patient in muscular dystrophy trial

    While there is a lot of excitement about the potential of gene therapies to treat DMD, with encouraging early results from a Sarepta phase I/II trial, these could be some ... Other therapeutic approaches under test for DMD include gene-editing with CRISPR

  • Daily Brief: GSK unveils R&D plan, Keytruda OK'd for lymphoma by NICE Daily Brief: GSK unveils R&D plan, Keytruda OK'd for lymphoma by NICE

    GSK says it will draw on 23andMe’s ability to identify patients with specific gene variations in specific diseases, in order to accelerate recruitment for new clinical studies. ... The company has also pledged to invest more in CRISPR - although recent

More from news
Approximately 2 fully matching, plus 23 partially matching documents found.

Latest Intelligence

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    That means gene products hitting that Glybera price of $1m are, for now at least, unlikely. ... CRISPR Therapeutics, one of the companies working with the exciting cutting-edge CRISPR/Cas9 gene editing technology, is looking to begin a phase I trial with

  • 30 women leaders in UK healthcare (part 3) 30 women leaders in UK healthcare (part 3)

    23. Dr Kathy Niakan, Developmental Biologist, The Francis Crick Institute. The last few years have seen a huge surge of interest in new gene editing tools that have enormous potential as ... The greatest excitement is reserved for CRISPR-Cas9 gene editing

  • Gene therapy Gene therapy

    the promise of gene therapy in the early nineties could not be remotely met. ... From a payload perspective, these include new technologies such as siRNA, Sleeping Beauty transposases, CRISPR-Cas9 gene editing, ARCUS gene editing, nucleic acid vaccines,

  • Deal Watch March 2017 Deal Watch March 2017

    Editas Medicine has entered a strategic R&D alliance where Allergan has exclusive access to Editas’s CRISPR genome-editing programmes in ocular health, as well as options to license up ... 100. Editas. Allergan. R&D alliance. LCA10 and up to four other

  • Winning the war against cancer Winning the war against cancer

    areas such as the gene-editing CRISPR technology.

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

  • Eric Rhodes becomes CEO of ERS Genomics Eric Rhodes becomes CEO of ERS Genomics

    In these roles, Rhodes was responsible for commercialising the company's genome editing technologies as well as driving its research and development. ... Biosciences. Foy said: “ With his deep understanding of the gene-editing landscape and extensive

  • Marc Becker joins CRISPR Therapeutics Marc Becker joins CRISPR Therapeutics

    Marc Becker joins CRISPR Therapeutics. He becomes chief financial officer. CRISPR Therapeutics has appointed Marc Becker as its new chief financial officer with remit to drive development of its gene-editing

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Training the next generation of biotech leaders

    Training the next generation of biotech leaders. Cell and gene therapy is no longer science fiction. ... It’ s such a disruptive advancement – it’ s just incredible to think it has all been made feasible through advancements in gene editing.”.

  • Perspective on biotech

    Find out about:. The emerging technologies revolutionising the biotech industry – from immunotherapy breakthroughs to cutting-edge gene editing techniques.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

The gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics